Onno van de Stolpe
Director/Board Member bij Institute For Human Organ & Disease Model Technologies
Oorsprong van het eerstegraads netwerk van Onno van de Stolpe
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
40
| Public Company | Biotechnology | 40 |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma.
7
| Extinct | Pharmaceuticals: Major | 7 |
| Extinct | Financial Conglomerates | 6 | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.
4
| Subsidiary | Biotechnology | 4 |
Wageningen University
4
| College/University | Other Consumer Services | 4 |
Institute For Human Organ & Disease Model Technologies
1
| Private Company | 1 | |
Introgene BV
1
| Extinct | Biotechnology | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Onno van de Stolpe via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Director/Board Member Chief Tech/Sci/R&D Officer | |
| GILEAD SCIENCES, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal Chief Executive Officer | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Charles River Discovery Research Services UK Ltd.
 Charles River Discovery Research Services UK Ltd. Miscellaneous Commercial ServicesCommercial Services Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal Director/Board Member | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Director/Board Member | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Chairman | |
| University of Bradford | College/University | Undergraduate Degree Doctorate Degree | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Investor | |
| Maastricht University | College/University | Graduate Degree Doctorate Degree | |
| University of Cambridge | College/University | Doctorate Degree Undergraduate Degree | |
Sterling Winthrop, Inc.
 Sterling Winthrop, Inc. Electronics/AppliancesConsumer Durables Part of GSK Plc, Sterling Winthrop, Inc. is a private company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million. | Electronics/Appliances | Corporate Officer/Principal Corporate Officer/Principal | |
AlpInvest Partners BV
 AlpInvest Partners BV Investment ManagersFinance AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands. | Investment Managers | Chief Executive Officer Director of Investments | |
| MITHRA PHARMACEUTICALS S.A. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Investor Relations Contact | |
| University of London | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of Amsterdam | College/University | Undergraduate Degree Graduate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| University of Leiden | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| Ghent University | College/University | Graduate Degree Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
The Royal Netherlands Academy of Arts & Sciences
 The Royal Netherlands Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Medical Distributors | Director/Board Member Chairman Founder | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| FOUNDATION MEDICINE INC | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member Director/Board Member | |
| University of Antwerp | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
| UNIQURE N.V. | Biotechnology | Chairman Chief Tech/Sci/R&D Officer | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Chief Executive Officer | |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Yale School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| DENALI THERAPEUTICS INC. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Chairman | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| PRIME MEDICINE, INC. | Biotechnology | Director/Board Member Director/Board Member | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
| OCULIS HOLDING AG | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 16 |
| Nederland | 13 |
| Verenigd Koninkrijk | 12 |
| België | 10 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 13 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 378 |
| Corporate Officer/Principal | 153 |
| Independent Dir/Board Member | 81 |
| Chairman | 68 |
| Chief Executive Officer | 56 |
Sterkste connecties
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Stephen Knight | 39 |
| Louise Ottilie Fresco | 33 |
| Martijn Kleijwegt | 33 |
| Vicki Sato | 28 |
| Ferdinand Verdonck | 25 |
| Anthony Adam Rosenberg | 23 |
| James Shannon | 22 |
| Staf van Reet | 22 |
| David Smith | 21 |
| Harrold van Barlingen | 20 |
| Daniel O'Day | 19 |
| Rudi Pauwels | 19 |
| Werner Cautreels | 18 |
| Graham Dixon | 18 |
- Beurs
- Insiders
- Onno van de Stolpe
- Bedrijfsconnecties
